Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Oct 4 - Oct 9
SGLT2, GLP-1 RA Combination Therapy Improves Cardiovascular, Kidney Outcomes in Diabetes Findings from a recent study are providing support for the combined use of sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists to optimize cardiovascular and kidney outcomes The collaborative meta-analysis Given the rapidly expanding indications for the use of GLP-1 receptor agonists, it was important to look at their effects with SGLT2 inhibitors, said Brendon L Neuen , MBBS, PhD, nephrologist and director of the Kidney Trials Unit at Royal North Shore Hospital and senior research fellow at The George Institute for Global Health , in a press release
IP-1: intervening peptide 1
Furthermore, the reduced glucagon levels can lead to a decrease in food intake and an increase in energy expenditure, resulting in a favorable shift toward weight loss
Nocatee residents get $100 offGLP-1 programs starting at just $99 first month
US$ 29.92
US$ 27.30
US$ 22.27
US$ 27.97
US$ 29.58
US$ 21.02
US$ 25.24
